BIO Bio-Rad Laboratories Inc - Class A

Price (delayed)

$372.35

Market cap

$10.01B

P/E Ratio

9.83

Dividend/share

N/A

EPS

$37.88

Enterprise value

$10.91B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 72

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

Highlights
The price to earnings (P/E) is 61% lower than the last 4 quarters average of 26.3
The equity has grown by 13% YoY and by 6% from the previous quarter
The company's quick ratio fell by 40% YoY

Key stats

What are the main financial stats of BIO

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
-3.54%
1 week
0.91%
1 month
2.18%
1 year
13.77%
YTD
22.89%
QTD
-1.42%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.59B
Gross profit
$1.33B
Operating income
-$61.9M
Net income
$1.02B
Gross margin
51.3%
Net margin
39.5%
BIO's operating income has dropped by 128% year-on-year
BIO's operating margin has dropped by 127% year-on-year

Price vs fundamentals

How does BIO's price correlate with its fundamentals

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
9.83
P/B
1.31
P/S
3.85
EV/EBIT
7.97
EV/EBITDA
7.97
EV/Sales
4.21
The price to earnings (P/E) is 61% lower than the last 4 quarters average of 26.3
BIO's P/B is 13% above its last 4 quarters average of 1.2 and 4.6% above its 5-year quarterly average of 1.3
The equity has grown by 13% YoY and by 6% from the previous quarter
The stock's price to sales (P/S) is 21% more than its last 4 quarters average of 3.3

Efficiency

How efficient is Bio-Rad Laboratories business performance

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's current ratio fell by 42% YoY
The company's quick ratio fell by 40% YoY
The debt is 82% smaller than the equity
Bio-Rad Laboratories's debt to equity has decreased by 14% YoY and by 5% from the previous quarter
The equity has grown by 13% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.